Acino International AG signed an agreement to acquire Portfolio of six South African prescription medicines from Aspen Pharmacare Holdings Limited (JSE:APN) for SAR 1.8 billion on October 22, 2021. The transaction includes the Trustan ® , Altosec ® , Zuvamor ® , Ciavor ® , Grantryl ® and Aspen Granisetron ® brands. In addition to secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement in terms of which Aspen will supply the Aspen manufactured products to Acino for a period of seven years.

The transaction is subject to customary closing conditions, including regulatory approvals. The transaction is expected to close by December 31, 2021. As of December 3, 2021, Aspen advised to its shareholders that it had received two unsolicited offers for its active pharmaceutical ingredient business and also confirmed that Aspen had decided to embark on a structured process to facilitate offers for all or parts of its API Business from those parties that submitted the unsolicited offers and other selected interested parties.

Shareholders are advised that this structured process remains ongoing and may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen's securities.